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Abstract 
Background: Rodent malaria parasites where the gene encoding circumsporozoite protein (CSP) has been replaced 
with csp genes from the human malaria parasites, Plasmodium falciparum or Plasmodium vivax, are used as pre‑clinical 
tools to evaluate CSP vaccines in vivo. These chimeric rodent parasites produce sporozoites in Anopheles stephensi 
mosquitoes that are capable of infecting rodent and human hepatocytes. The availability of chimeric P. falciparum 
parasites where the pfcsp gene has been replaced by the pvcsp would open up possibilities to test P. vivax CSP vac‑
cines in small scale clinical trials using controlled human malaria infection studies.
Methods: Using CRISPR/Cas9 gene editing two chimeric P. falciparum parasites, were generated, where the pfcsp 
gene has been replaced by either one of the two major pvcsp alleles, VK210 or VK247. In addition, a P. falciparum para‑
site line that lacks CSP expression was also generated. These parasite lines have been analysed for sporozoite produc‑
tion in An. stephensi mosquitoes.
Results: The two chimeric Pf‑PvCSP lines exhibit normal asexual and sexual blood stage development in vitro and 
produce sporozoite‑containing oocysts in An. stephensi mosquitoes. Expression of the corresponding PvCSP was 
confirmed in oocyst‑derived Pf‑PvCSP sporozoites. However, most oocysts degenerate before sporozoite formation 
and sporozoites were not found in either the mosquito haemocoel or salivary glands. Unlike the chimeric Pf‑PvCSP 
parasites, oocysts of P. falciparum parasites lacking CSP expression do not produce sporozoites.
Conclusions: Chimeric P. falciparum parasites expressing P. vivax circumsporozoite protein fail to produce salivary 
gland sporozoites. Combined, these studies show that while PvCSP can partially complement the function of PfCSP, 
species‑specific features of CSP govern full sporozoite maturation and development in the two human malaria 
parasites.
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Background
Plasmodium sporozoites enter the blood stream through 
the bite of an infectious mosquito, after which they 
quickly migrate to the liver and invade hepatocytes. 
After multiplication within hepatocytes, merozoites are 
formed and released into the blood stream where they 
invade erythrocytes. Proteins of the pre-erythrocytic 
life cycle stages, sporozoites and liver stages, are attrac-
tive vaccine targets and are the principal components 
of leading malaria vaccines against the human parasites 
Plasmodium falciparum and Plasmodium vivax [1–4]. 
The target antigen of the most advanced P. falciparum 
malaria vaccine (RTS,S) is the circumsporozoite protein 
(CSP), the major sporozoite surface protein [5, 6] and is 
also an important vaccine target for P. vivax [7, 8]. CSP 
plays a critical role both in sporozoite formation and in 
sporozoite invasion of mosquito salivary glands and liver 
cells of the host [9–12]. So far, pre-erythrocytic subunit 
malaria vaccines, including RTS,S, have shown low to 
modest protective efficacy, both in the clinic and in field 
studies [13–16]. Efforts to increase the protective efficacy 
of malaria vaccines is focussed on identifying novel anti-
gens, combining multiple antigens in a vaccine and by 
improving the delivery and immunogenicity of these anti-
gens by using a variety of novel immunization platforms.
Testing the next generation of P. falciparum vaccines 
and vaccine formulations is greatly aided by the ability to 
vaccinate individuals and then examine vaccine efficacy 
by infecting them with malaria-parasites in so-called con-
trolled human malaria infections (CHMI) [17–20]. CHMI 
studies have increased the speed of vaccine evaluation by 
using well-controlled early-phase proof-of-concept clini-
cal studies. Such studies facilitate the down-selection of 
vaccine candidates and identifying those most suitable 
for further evaluation in more expensive and difficult 
phase 2 and 3 trials in areas where malaria is endemic.
Although recently CHMI has also been developed for 
P. vivax [21] and has been applied to assess pre-eryth-
rocytic vaccine candidates [22, 23], the use of P. vivax 
CHMI to rapidly screen different P. vivax vaccines is 
limited because of the lack of methods to continuously 
propagate P. vivax blood stages in culture and to produce 
gametocytes in vitro that can be used to infect mosqui-
toes to produce sporozoites for challenge infections [21]. 
Therefore, P. vivax CHMI is dependent on sporozoites 
that have been obtained from mosquitoes fed on infected 
patients [21]. Moreover, P. vivax sporozoites can produce 
hypnozoites, dormant forms that can persist in the liver 
for prolonged periods, which requires safe and effective 
means to clear these forms from the liver in CHMI stud-
ies [21, 24].
In preclinical evaluation of vaccines, chimeric 
rodent parasites expressing P. falciparum and P. vivax 
pre-erythrocytic antigens have been used to analyse 
protective immune responses induced by P. vivax or P. 
falciparum vaccines in vivo in mice. These chimeric par-
asites have been used to assess the protective immune 
responses induced by vaccination that influence sporo-
zoite invasion of hepatocytes both in  vitro and in  vivo 
and the removal of infected hepatocytes in  vivo [25]. 
For example, chimeric rodent malaria parasites have 
been generated where the endogenous csp gene has been 
replaced either with pfcsp or different pvcsp alleles. These 
chimeric parasites produce sporozoites that are infec-
tious to rodent hepatocytes in  vivo and human hepato-
cytes in culture [25].
Based on the studies with chimeric rodent parasites 
we reasoned that the availability of chimeric P. falcipa-
rum parasites that express P. vivax antigens would open 
up possibilities to analyse protective immune responses 
induced by vaccination using P. vivax antigen-based vac-
cines in CHMI bypassing the need for P. vivax parasite 
production and measures to ensure that P. vivax hypno-
zoites are removed. As a proof of concept two chimeric P. 
falciparum parasites were generated using CRISPR/Cas9 
gene editing methodologies, where the pfcsp gene was 
replaced by one of the two major pvcsp alleles, VK210 and 
VK247 [26]. These chimeric lines, pf-pvcsp(vk210) and 
pf-pvcsp(vk247), had wild type-like blood stage develop-
ment and produced normal numbers of oocysts. Unlike 
the absence of sporozoite formation in pfcsp deletion par-
asites, sporozoite formation did occur inside oocysts of 
both chimeric lines; however between 50 and 90% of the 
oocysts degenerated before sporozoite formation and no 
sporozoites were detected sporozoites in salivary glands. 
The lack of complete functional complementation was 
unexpected, since chimeric rodent Plasmodium berghei 
parasites expressing PvCSP-VK210 and PvCSP-VK247 
are able to produce salivary gland sporozoites in An. ste-
phensi mosquitoes that are infective to mice [27, 28]. The 
findings in this study and the species-specific features of 
CSP that may govern full maturation and development of 
sporozoites of the two human malaria-parasite species 
are discussed.
Methods
Plasmodium falciparum and Plasmodium berghei parasites 
and in vitro cultivation of P. falciparum blood stages
Plasmodium falciparum parasites from the NF54 strain 
[29] were obtained from the Radboud University Medi-
cal Center (Nijmegen, The Netherlands). Parasites were 
cultured following the standard conditions in RPMI-
1640 culture medium supplemented with l-glutamine 
and 25  mM HEPES (Gibco Life Technologies), 50  mg/l 
hypoxanthine (Sigma). Culture medium was supple-
mented with 10% human serum and 0.225%  NaHCO3. 
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Parasites were cultured at a 5% haematocrit under 4%  O2, 
3%  CO2 and 93%  N2 gas-conditions at 75 rpm at 37 °C in 
a semi-automated culture system in 10 ml flasks (Infers 
HT Multitron and Watson Marlow 520U). Fresh human 
serum and human red blood cells (RBC) were obtained 
from the Dutch National Blood Bank (Sanquin Amster-
dam, the Netherlands; permission granted from donors 
for the use of blood products for malaria research and 
microbiology test for safety). RBC of different donors 
were pooled every 2 weeks, washed twice in serum free 
RPMI-1640 and suspended in complete culture medium 
to 50% haematocrit. Human serum of different donors 
were pooled every 4–6  months and stored at − 20  °C 
until required.
In addition, P. falciparum gametocytes cultures were 
generated using standard culture conditions (see above) 
with some modifications [30]. Briefly, parasites from 
asexual stage cultures were diluted to a final parasitae-
mia of 0.5% and cultures were followed during 14  days 
without refreshing RBC. After 9 days these cultures were 
treated with 50 mM of N-acetyl-D-glucosamine (Sigma) 
to kill asexual stages and to enrich for gametocytes. At 
day 14 the cultures were analysed for mature, stage V, 
gametocytes.
Four different mutant lines of the rodent parasite P. 
berghei were used that have been previously reported. (i) 
A transgenic reference line of P. berghei ANKA, express-
ing the fusion protein GFP-Luciferase (line 676m1cl1; 
PbΔp230p; RMgm-29; https ://www.pberg hei.eu) [31]; 
(ii) A mutant that expresses P. vivax CSP (VK210 allele). 
In this mutant the pbcsp gene has been replaced with 
the pvcsp-vk210 gene (line 2196cl1; RMgm-4136; https 
://www.pberg hei.eu); [27]; (iii) A mutant that expresses 
PvCSP (VK247 allele). In this mutant the pbcsp gene has 
been replaced with the pvcsp-vk247 gene (line 2199cl1; 
RMgm-4137; https ://www.pberg hei.eu; [27];
Generation and selection of the chimeric lines 
pf‑pvcsp(vk210) and pf‑pvcsp(vk247)
In order to create pf-pvcsp(vk210) and pf-pvcsp(vk247), 
the previously described pLf0019 construct, contain-
ing the cas9 gene was used [32] and 2 different sgRNA-
donor DNA containing plasmids, pLf0042 (targeting 
PfCSP and containing the pvcsp-vk210 gene) and pLf0043 
(containing the pvcsp-vk247). The pLf0019 construct 
contains a blasticidin (BSD) drug-selectable marker cas-
sette and both sgRNA-donor DNA constructs (pLf0042 
and pLf0043) contain a hdhfr drug-selectable marker cas-
sette for selection with WR99210. To generate pLf0042 
and pLf0043, plasmid pLf0033 (see Additional file 1) was 
modified by introducing two homology regions target-
ing Pfcsp (PF3D7_0304600). Homology region 1 (HR1) 
was amplified using primers P1/P2 and homology region 
2 (HR2) with P3/P4 from P. falciparum NF54 genomic 
DNA (see Additional file 2 for primer details). HR1 was 
cloned in pLf0033 using restriction sites kpnI/EcoRI and 
HR2 using EcoRI/AatII. The pvcsp alleles pvcsp-vk210 
(GenBank accession number P08677; Belem strain) and 
pvcsp-vk247 (GenBank accession number M69059.1; 
Papua New Guinea strain) were amplified from existing 
plasmids PbG01-PvCSP-vk247 and PbG01-PvCSP-vk210 
[27] using the primers P5/P6 and cloned into pL0033 
containing the HR using restriction sites EcoRV/EcoRI, 
resulting in intermediate plasmids pLf0040 and pLf0041 
(pvcsp-vk210 and pvcsp-vk247; see Additional file 1). An 
additional plasmid, AS301 (see Additional file  1) was 
used to clone the guide sgRNA (AS301-sgRNA2) spe-
cific for pfcsp. The sgRNA sequence was identified using 
the Protospacer software (alphaversion; https ://sourc 
eforg e.net/proje cts/proto space rwb/files /Relea se/) and 
was amplified using the primers P7/P8. This sgRNA was 
selected based on the best-off targets hits score through-
out the genome given by Protospacer and the total num-
ber of mismatches of the sgRNA with respect to the PAM 
site. A 20  bp guide sgRNA sequence, flanked on both 
sides by a 15 bp DNA sequence necessary for In Fusion 
cloning (HD Cloning Kit; Clontech), was annealed and 
used to replace the BtgZI adaptor as previously described 
[33]. The construct was then digested with BlnI and NruI 
to evaluate the successful cloning of the sgRNA and later 
confirmed by Sanger sequencing using primers P9/P10. 
Finally, the AS301-sgRNA2 was digested with EcoRV/
ApaI and cloned into the vectors pLf0040 and Plf0041 
using the restriction sites StuI/ApaI resulting in the final 
constructs pLf0042 and pLf0043 (see Additional file 1).
Plasmids for transfection were isolated from 250  ml 
cultures of Escherichia coli XL10-Gold Ultracompetent 
Cells (Stratagene) by maxi-pep (using  HiSpeed® Plas-
mid Maxi Kit  (Qiagen®)) to generate 25–50  µg of DNA 
used per transfection. Transfections of P. falciparum 
NF54 parasites were performed using ring stage parasites 
obtained from cultures with a parasitaemia of 6–15% 
that were synchronized by 5% d-sorbitol treatment 
2  days before transfection [34]. Infected RBC were pel-
leted by centrifugation (1150g, 5 min) and 300 µl of the 
pelleted cells were transferred to a 0.2  cm cuvette and 
mixed with ~ 50  µg of each circular plasmid (Cas9 and 
sgRNA/Donor DNA constructs) in 100 µl cytomix [35]. 
Electroporation was performed with a single pulse (310 V 
and 950 µF) in the Biorad Gene Pulser Xcell electropora-
tor (including CE- and PC module) and cells were imme-
diately transferred in a 10  ml culture flask and cultures 
were maintained under standard conditions in the semi-
automated culture system (see above). Selection of trans-
formed parasites was performed by applying ‘double’ 
positive selection 24 h after transfection using the drugs 
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WR99210 (2.6  nM) and BSD (5  µg/ml). For WR99210 
100 µl of a stock solution (2.6 µM) was added to 100 ml 
complete culture medium resulting in a final concentra-
tion of 2.6 nM. To prepare the WR99210 stock-solution 
WR99210 was dissolved in DMSO (100  mM). For BSD 
50 µl of a stock solution (10 mg/ml) was added to 100 ml 
complete culture medium resulting in a 5  µg/ml final 
concentration. Drug pressure in the cultures was main-
tained until thin blood-smears were parasite-positive 
(usually after 14–26  days). Positive selection will select 
for the parasites that were transfected successfully with 
both plasmids (Cas9 and sgRNA/Donor constructs). Sub-
sequently, both drugs were removed from the cultures 
for 2–4  days, followed by applying negative selection 
by addition of 5-Fluorocytosine (5-FC; 130 µl of a stock 
solution (0.77  mM) in 100  ml complete medium with a 
final concentration of 1  µM; [36]) in order to eliminate 
parasites that retained the crRNA/Donor construct as 
episomal plasmid and enrich for the transfected parasites 
containing the donor DNA integrated into the genome. 
Negative drug pressure in the cultures was maintained 
until thin blood-smears were parasite-positive (usu-
ally after 7  days). After negative selection infected RBC 
(iRBC) were harvested from cultures with a parasitaemia 
of 4–10% for genotyping by diagnostic PCR and South-
ern blot analysis. Subsequently, selected parasites were 
cloned by limiting dilution.
Generation and selection of the PfΔcsp line
In order to create the PfΔcsp line, a new plasmid 
(pLf0070: that contain both the crRNA and the Cas9-
expression cassette, was modified in order to introduce 
sgRNAs against Pfcsp. This plasmid, kindly obtained from 
Dr. Marcus Lee (Wellcome Trust Sanger Institute, Well-
come Genome Campus, Hinxton, Cambridgeshire, UK) 
is based on plasmid pDC2-cam-Cas9-U6.2-hdhfr [37] 
with a smaller U6 cassete (693 bp) and with the Cas9 gene 
harmonized to P. falciparum. Two plasmids with two dif-
ferent sgRNAs (026 and 012) were generated. Briefly, 
pLf0070 was digested with BbsI and sgRNA026 was 
cloned using the primers P11/P12 and sgRNA012 using 
the primers P13/P14. The primers (100 µM each primer) 
were phosphorylated with T4 polynucleotide kinase (10 
Units per reaction) during 30 min at 37  °C, followed by 
an annealing program of 5 min incubation at 94  °C and 
a ramp down to 25 °C at 5 °C per min, and subsequently 
ligated into the vector using T4 ligase (5 units) resulting 
in plasmid pLf0071 and plasmid pLf0072 (see Additional 
file  1). A second DNA donor plasmid was generated by 
replacing the Pvcsp-vk210 gene of the pLf0040 construct 
(see above) by an mCherry expression cassette obtained 
from an intermediate plasmid pLf0055 (see Additional 
file  1). In this cassette mCherry is under control of the 
promoter region of gapdh (GeneID PF3D7_1462800) 
and the 3′UTR of histidine-rich protein II(GeneID 
PF3D7_0831800). The complete mCherry expression 
cassette was removed from pLf0055 by digestion with 
the EcoRI/NruI and cloned into pLf0040 digested with 
EcoRI/EcoRV resulting in the DNA donor vector pLf0083 
(see Additional file 1). This donor DNA construct has a 
drug selectable marker cassette containing a fusion of the 
positive selectable marker hdhfr and the negative selecta-
ble marker yfcu (yeast cytosine deaminase/uridyl phos-
phoribosyl transferase).
Transfections of P. falciparum NF54 parasites was per-
formed by spontaneous plasmid uptake from plasmid-
loaded red blood cells cultured under static conditions 
[38]. Briefly, 300  µl of pelleted, uninfected RBC were 
transferred to a 0.2 cm cuvette and mixed with 50 µg of 
both sgRNA constructs (25  µg of pLf0071 and 25  µg of 
pLf0072) and 50  µg of the donor construct (pLf0083) 
suspended in 200  µl of cytomix. Electroporation was 
performed as described in the previous section. After 
electroporation of the uninfected RBC, iRBC containing 
P. falciparum NF54 parasites were added to a concentra-
tion of 0.1%. Selection of transformed parasites was per-
formed when cultures reached a parasitaemia of 3% (after 
approx. 3 days) with 100 µl of WR992010 (2.6 nM) during 
a period of 6 days. Subsequently the drug was removed 
and parasites were harvested at 0.8% of parasitaemia for 
mCherry fluorescence microscopy analysis to determine 
the ratio of wild type and mutant parasites present in the 
population. Parasites were collected from cultures that 
contained > 80 mCherry-positive parasites (at a 4–10% 
parasitaemia) for genotyping by diagnostic PCR and 
Southern blot analysis and for cloning (see next section).
Cloning of transfected P. falciparum parasites
Based on the PCR confirmation of the integration, the 
transfected parasites were cloned by the method of lim-
iting dilution as previously described [39] with minor 
modifications. Briefly, infected RBC from cultures with a 
4 to 10% parasitaemia were diluted with uninfected RBC 
to  105 iRBC/100  µl in 2  ml culture medium (1% haem-
atocrit and 20% serum). Serial dilutions were then per-
formed with uninfected RBC in complete medium (1% 
haematocrit and 20% serum) and cultured in a total vol-
ume of 100 µl incubated in 96 well plates, resulting in 8 
rows with the following numbers of iRBC per well: 100, 
10, 5, 2.5, 1.25, 0.6, 0.3, 0.15. Plates were incubated in a 
Candle Jar at 37  °C and culture medium was changed 
every other day. Every 5 days RBC were added resulting 
in an increase of the haematocrit from 1 to 5%. Between 
days 10–14 samples were collected for thick smear anal-
ysis from the rows with the highest numbers of iRBC/
well; 50 µl medium was removed and from the remaining 
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culture 5 µl was used directly for preparing thick smears. 
At day 21 thick smears were made from all rows. Clones 
were selected from dilutions/row with less than 30% of 
the wells parasite positive. These clones were transferred 
in 10 ml culture flasks at 5% haematocrit under standard 
culture conditions (see previous sections) in the semi-
automated culture system for collection of parasites for 
further genotype and phenotype analyses.
Genotyping of the pf‑pvcsp(vk210), pf‑pvcsp(vk247) 
and pfΔcsp lines
For genotyping of the chimeric pf-pvcsp lines and the 
pfΔcsp line diagnostic PCR and Southern blot analysis 
of digested DNA were performed from material isolated 
from iRBC obtained from 10  ml cultures (parasitaemia 
3–10%), pelleted by centrifugation (1150g; 5 min.). RBC 
were then lysed with 5–10 ml of cold (4 °C) erythrocyte 
lysis buffer (10 × stock solution 1.5  M  NH4Cl, 0.1  M 
 KHCO3, 0.01  M  Na2EDTA; pH 7.4; [34]) and parasites 
were treated with RNAse and proteinase-K before DNA 
isolation by standard phenol–chloroform methods. Cor-
rect integration of the donor constructs was analysed by 
standard and long-range PCR (LR-PCR). In brief, for the 
chimeric pf-pvcsp lines integration of the pvcsp cassettes 
was confirmed by LR-PCR using the primers P15/P16 
(and analysed by EcoRV digestion). The PCR-amplified 
product was cloned in a TopoTA vector for sequencing 
(see Additional file 3 for details of the primers and Addi-
tional file  2 for sequence data). The LR-PCR fragments 
were amplified using KOD Hot start polymerase follow-
ing standard conditions with an annealing temperature 
of 53.5  °C for 15  s and an elongation step of 68  °C for 
9  min. For the PfΔcsp line, 5′-integration PCR was per-
formed using the primers P15/P19 and to confirm the 
presence of the mCherry gene PCR was performed with 
the primers P20/P21. The PCR fragments were amplified 
using Go-taq® DNA polymerase (Promega) following 
standard conditions with an annealing temperature of 
56  °C for 20 s and a elongation step of 72  °C for 4 min. 
All other PCR settings were according to manufacturer’s 
instructions.
Southern blot analysis for the chimeric pf-pvcsp 
lines was performed with genomic DNA digested with 
AvaII (4  h at 37  °C) in order to confirm integration of 
the replacement of pfcsp by the pvcsp genes Fig.  1c). 
Digested DNA was hybridized with probes targeting the 
Pfcsp homology region 2 (HR2), amplified from NF54 
genomic DNA by PCR using the primers P3/P4 and a 
second probe targeting ampicillin (Amp) gene, obtained 
by digestion of the intermediate plasmid pLf0040 with 
AatII/PvuI (550 bp). For Southern blot analysis of PfΔcsp, 
genomic DNA was digested with AvaII and XhoI (4 h at 
37 °C) and digested DNA was hybridized with the same 
probes used with the Pf-Pvcsp lines (HR2 and Amp 
probes see Additional file 7C).
Phenotype analysis of P. falciparum parasites: blood stages, 
gametocytes, oocysts and sporozoites
The growth rate of asexual blood stages of the pf-pvcsp 
and pfΔcsp lines was monitored in 10 ml cultures main-
tained in the semi-automated culture system under 
standard culture conditions (see above). Briefly, a 0.5% 
parasitaemia culture was established in complete culture 
medium at a haematocrit of 5%. Medium was changed 
twice daily and the culture maintained for a period of 
5  days without refreshing RBC. For determination of 
the course of parasitaemia, triplicate samples of 100  µl 
were collected daily from all cultures and cells pelleted 
by centrifugation (9485g; 30 s) and stained with Giemsa. 
mCherry expression of in PfΔcsp blood stages was ana-
lysed by standard fluorescence microscopy. In brief, 
200 µl samples were collected from 10 ml cultures with 
a parasitaemia between 4 and 10% and stained with the 
DNA-specific dye Hoechst-33342 by adding 4  µl of a 
(See figure on next page.)
Fig. 1 Generation and genotyping of two chimeric P. falciparum parasites (Pf‑pvcsp). a Two Pf‑pvcsp parasite lines were generated using CRISPR/
Cas9 methodology. The coding sequence (CDS) of Pfcsp gene was replaced by insertion of the Pvcsp(vk210) and Pvcsp(vk247) CDS using donor‑DNA 
plasmids pLf0042 and pLf0043. A schematic representation of the Pfcsp locus before and after insertion of the construct showing the location of 
the restriction sites (A: AvaII, E: EcoRV), sizes (in bp) of restriction fragments (red for Southern blot analysis), location of primers (p), PCR amplicons 
and sizes (in bp) of the fragments (in black (b, c). HR1, HR2: Pfcsp homology (targeting) regions. The figure is not shown to scale. Primer sequences 
can be found in Additional file 2. b Diagnostic PCR and long‑range PCR (LR‑PCR) confirming the correct integration of the Pvcsp CDS into the PfCSP 
locus. Diagnostic PCR: Pfcsp open reading frame (lane 2; primers p17/p18); Pvcsp open reading frame (lane 3; primers p5/p6); P. falciparum sequestrin 
gene as a control gene (lane 1; primers p22/p23). LR‑PCR: products were run undigested or digested with EcoRV (LR‑PCR + E) in order to confirm 
double cross‑over recombination. LR‑PCR (lane 4) of cloned parasites of Pf‑pvcsp(vk210)(cl7; primers p15/p16), Pf‑pvcsp(vk247)(cl5; primers p15/p16) 
and WT. LR‑PCR fragments digested with EcoRV (lane 5) for confirmation of double cross‑over integration. c Southern blot analysis of AvaII restricted 
DNA of WT and chimeric Pf‑Pvcsp parasites confirms the specific integration of the Pvcsp genes into the pfcsp gene locus. DNA was hybridized with 
a probe targeting the homology region 2 of pfcsp (upper panels; HR2; primers p3/p4; see a In addition, to show absence of donor‑DNA plasmid 
and single cross‑over events, DNA was hybridized with a probe for the ampicillin gene (lower panels; intermediate donor‑DNA plasmid pLf0040 
digested with AatII and PvuI). The hybridization pattern observed with the HR2 probe identified the expected different‑sized DNA fragments in WT 
and pf‑pvcsp parasites (2057 and 5294 bp)
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500  µM stock-solution (final concentration 10  µM) for 
20 min at 37 °C. Subsequently, a 5 µl drop was placed on a 
microscopic slide (mounted under a cover slip) and fluo-
rescence in live iRBC analysed using a Leica fluorescence 
MDR microscope (100× magnification). Pictures were 
recorded with a DC500 digital camera microscope using 
Leica LAS X software and with the following exposure 
times: mCherry 0.6 s; Hoechst-33342 0.136 s; bright field 
0.62 s (1× gain).
Gametocyte production by the pf-pvcsp and pfΔcsp 
lines was analysed in gametocyte cultures, established 
as described in the previous sections. To activate game-
tocytes for exflagellation 20 µl samples of the P. falcipa-
rum stage V gametocyte cultures at day 14 were diluted 
a
b
c
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1:1 with FCS at room temperature. Gametes and exflagel-
lation centres were examined and quantified 10–20 min 
after activation using a Bürker cell counter. For analysis 
of mosquito stages (oocysts and sporozoites) of the chi-
meric pf-pvcsp lines, An. stephensi were infected using 
the standard membrane feeding assay (SMFA) [40, 41]. 
Oocysts were analysed between day 8 and 14 for sporozo-
ite production and the percentage of degenerated oocyst 
determined. Oocysts were qualified as degenerated based 
on the following criteria: no sporozoite formation visible 
and oocyst cytoplasm vacuolated. Salivary gland sporo-
zoites were counted at day 14 and 21 post feeding. For 
counting sporozoites, salivary glands from 30 to 60 mos-
quitoes were dissected and homogenized using a grinder 
in 100 µl of RPMI pH 7.2 and sporozoites were analysed 
in a Bürker cell counter using phase-contrast microscopy.
Analysis of PvCSP expression in oocyst‑derived sporozoites 
of the pf‑pvcsp(vk210) and pf‑pvcsp(vk247) lines
To analyse CSP expression in oocyst-derived sporozoites 
of the pf-pvcsp lines by immunofluorescence microscopy, 
midguts from 30 to 60 An. stephensi mosquitoes were 
collected in an eppendorf tube at day 10 after feeding in 
RPMI-1640 medium containing 3% BSA. Midguts were 
mechanically crushed using a grinder and centrifuged 
with low speed (62g) for 3  min at 4  °C. Subsequently, 
the supernatant containing oocyst-derived sporozoites 
was collected for fluorescence microscopy and samples 
(20 µl) were placed on a 8-well black cell-line diagnostic 
microscope slide (Thermo Scientific), dried for 10  min, 
and fixed with 4% paraformaldehyde for 30 min at room 
temperature. After fixation the slides were washed 
three times with 1× PBS and permeabilized with 20  µl 
of 0.5% triton in 1× PBS and then blocked with 10% of 
FCS in 1× PBS for 1 h. Fixed cells were washed with 1× 
PBS and incubated with monoclonal antibodies against 
PvCSP(vk210) (mouse, anti-PvCSP-VK210 MAb (MR4); 
1:200 dilution of 109 µg/ml stock solution [27]) PvCSP-
(vk247) (mouse, anti-PvCSP-VK247 MAb (MR4); 1:200 
dilution of 125  µg/ml [27]), PfCSP (mouse, anti-PfCSP 
(210 A) MAb(MR4); 1:200 dilution of 8 µg/ml stock solu-
tion REF) and PfHSP70 (rabbit, anti-PfHSP70; 1:200 dilu-
tion of 100 µg/ml stock solution StressMarqBiosciences) 
for 1  h at room temperature. Subsequently, cells were 
rinsed three times with 1× PBS and incubated with the 
secondary antibodies Alexa  FLuor®488/594-conjugated 
chicken anti-mouse and anti-rabbit (Invitrogen Detec-
tion technologies at 1:200). Finally, the cells were washed 
again three times with 1× PBS and stained with the 
DNA-specific dye Hoechst-33342 at a final concentration 
of 10 µM. Fixed cells were covered with 1–2 drops of an 
anti-fading agent (Vectashield), and a coverslip placed on 
the cells and sealed with nail polish. Stained cells were 
analysed for fluorescence using a Leica fluorescence 
MDR microscope (100× magnification). Pictures were 
recorded with a DC500 digital camera microscope using 
Leica LAS X software with the following exposure times: 
Alexa 488: 0.7 s; Alexa 594: 0.6 s Hoechst 0.136 s; bright 
field 0.62 s (1× gain).
Phenotype analysis of Plasmodium berghei parasites: 
oocysts, sporozoites and sporozoite infectivity
Feeding of An. stephensi mosquitoes with P. berghei para-
sites, determination of oocyst production and sporozoite 
collection were performed as described [27]. Determina-
tion of parasite liver load by in vivo imaging and determi-
nation of the prepatent period in mice after intravenously 
injection of 1000 salivary gland sporozoites was per-
formed as described [27].
Statistics
Data were analysed using GraphPad Prism software 
package 5.04 (GraphPad Software, Inc). Significance dif-
ference analyses between WT, pf-pvcsp and the pfΔcsp 
lines was performed using the unpaired Student’s t-test.
Results
Generation of two chimeric P. falciparum parasites lines 
expressing PvCSP‑210 or PvCSP‑247
Using CRISPR/Cas9 gene editing, two chimeric P. falci-
parum parasites lines were created, pf-pvcsp(vk210) and 
pf-pvcsp(vk247), where the P. falciparum csp gene has 
been replaced by either one of the two major P. vivax csp 
alleles, VK210 and VK247. A previously described Cas9 
construct (pLf0019), containing the Cas9 expression cas-
sette with a blasticidin (BSD) drug-selectable marker 
cassette [32], was used in combination with two sgRNA 
donor-DNA containing plasmids, pLf0042 and pLf0043. 
These constructs are used to target the pfcsp gene locus 
and as ‘DNA-donor’ sequences they replace pfcsp with 
either pvcsp-vk210 or the pvcsp-vk247 full-length gene 
coding sequences (Fig. 1). The coding sequences of pvcsp-
vk210 (GenBank accession number P08677; Belem strain) 
and pvcsp-vk247 (GenBank accession number M69059.1; 
Papua New Guinea strain) were amplified from exist-
ing plasmids P. bergheiG01-PvCSP-vk247 (pL1943) and 
P. bergheiG01-PvCSP-vk210 (pL1942) [27]. The two 
homology regions targeting pfcsp (PF3D7_0304600) 
were amplified from genomic P. falciparum DNA (NF54 
strain). Both constructs contain a hdhfr-yfcu drug-
selectable marker cassette.
Transfections of P. falciparum NF54 parasites were 
performed using synchronized ring stage parasites that 
were transfected with ~ 50  µg of each circular plasmid 
(Cas9 and sgRNA/donor-DNA constructs; see Additional 
file 1) and selection of transformed parasites containing 
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both plasmids (Cas9 and sgRNA/donor-DNA constructs) 
was performed by applying ‘double’ positive selection 
with the drugs WR99210 and BSD, until parasites were 
detectable by thin blood-smear analysis (between day 14 
and 26 post transfection). Subsequently, parasites were 
cultured for 2–4 days without drugs, followed by apply-
ing negative selection to eliminate parasites that retained 
the transfection constructs (i.e. donor-DNA) as episomal 
plasmids and to enrich for transfected parasites in which 
the donor-DNA construct has integrated into the para-
site genome. Genotyping of selected parasite populations 
by long-range PCR revealed that both pvcsp(vk210) and 
pvcsp(vk247) cassettes had integrated into the P. falci-
parum genomes (Fig.  1b) and Southern blot analysis of 
cloned lines confirmed correct integration of the con-
structs (Fig. 1c). Phenotype analyses, as described below, 
were performed using pf-pvcsp(vk210) clone 7 and pf-
pvcsp(vk247) clone 5. Sequence analysis of the long-range 
PCR products confirmed the correct sequence of pvcsp 
genes and replacement of the pfcsp gene in both pf-pvcsp 
lines (see Additional file 3).
Pf‑PvCSP210 and Pf‑PvCSP210 parasites form oocysts 
but salivary gland sporozoites are absent in An. stephensi 
mosquitoes
The growth of asexual blood stages in cultures and game-
tocyte production of both pf-pvcsp lines was comparable 
to that of the parental P. falciparum NF54 wild type (WT) 
parasite strain (see Additional file  4, Table  1). Gameto-
cyte cultures of the pf-pvCSP lines produced WT-like 
numbers of mature, stage V, gametocytes of both sexes. 
Mature male gametocytes of both lines underwent 
exflagellation upon activation and were able to form male 
gametes (Table 1).
Anopheles stephensi mosquitoes were fed with either 
WT gametocytes or gametocytes of the pf-pvcsp lines 
using the standard membrane feeding assay and the 
number of oocysts in mosquito midguts was determined 
at day 10 post infection and the presence of sporozoites 
in the haemocoel and salivary glands was analysed at day 
14 and day 21. Dissection of WT and pf-pvcsp infected 
mosquitoes revealed that all lines produced compara-
ble numbers of oocysts; however, no sporozoites were 
detected in salivary glands in mosquitoes infected with 
either of the pf-pvcsp lines (Table 1). Moreover, no sporo-
zoites from the pf-pvcsp lines were found in haemocoel 
fluid after mosquito dissection; in contrast, when WT 
infected mosquitoes were dissected many sporozoites 
were observed in haemocoel fluid.
These observations indicate that the chimeric parasites 
expressing PvCSP are unable to produce sporozoites that 
are competent in invading salivary glands.
pf‑pvcsp lines produce sporozoites in oocysts but most 
oocysts degenerate before sporozoite formation 
and release of sporozoites
For two Plasmodium species it has been shown that csp 
deletion mutants can form oocysts; however by light-
microscopy, these oocysts are highly vacuolated and do 
not show signs of sporozoite formation [42, 43]. There-
fore, oocyst development of pf-pvcsp was analysed in 
greater detail by light microscopy and PvCSP expres-
sion was examined by immunofluorescence microscopy. 
After feeding with both pf-pvcsp lines, oocysts were 
Table 1 Gametocyte, oocyst and sporozoite production in WT, pf-pvcsp(vk210), pf-pvcsp(vk247) and PfΔcsp 
a Mean percentage of stage V male (m) and female (f ) gametocytes (per 100 red blood cells) in day 14 cultures in 2–7 experiments (exp.)
b Mean number of exflagellating male gametocytes (per  105 red blood cells) at 10–20 min after activation of day 14 gametocyte cultures (sd standard deviation)
c Mean number of oocyst per mosquito at day 9–10 after feeding. Range corresponds to the mean number of retorts in multiple experiments (1–5 exp. per line; 10–30 
mosquitoes per exp.)
d Mean number of salivary gland sporozoites per mosquito at day 21 after feeding. Range corresponds to the mean number of sporozoites in multiple experiments 
(1–5 exp. per line; 20–30 mosquitoes per exp.)
Lines No of gametocytes stage V male/
female mean (SD)a
No. of exflagellation 
mean (SD)b
No. of oocyst mean (range)c No of  sporozoitesd
WT
 NF54 (n = 4) m: 0.6 (0.2) f: 1.3 (0.3) (3 exp.) 1436 (191) (3 exp.) 28.2 (13–54) (4 exp) 9–20 K (4 exp)
pf‑pvcs(vk210)
 0050cl7 (n = 5) m: 0.6; f: 1.1 (1 exp.) 2030 (916) (3 exp.) 44.2 (30–63) (5 exp) Negative
 0050cl2 (n = 1) ND ND 9.1 (1 exp.) Negative
pf‑pvcs(vk247)
 0041cl5 (n = 3) m: 0.8; f:1.5 (1 exp.) 460 (34) (3 exp.) 23.1 (17–40) (3 exp.) Negative
PfΔcsp
 0113cl1 (n = 1) ND 875 (1 exp.) 4.6 Negative
 0113cl3 (n = 2) m: 0.6 f: 1.1 (1 exp.) 1010 (388) (3 exp.) 2.2 and 3.2 (2 exp.) Negative
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readily detected at day 10, in which sporozoite forma-
tion occurred (Fig.  2a). However, analysis of oocysts 
between day 10 and 14 showed that most oocysts started 
to degenerate before full maturation as shown by the 
absence of clear sporozoite formation and the presence 
of large vacuoles in the cytoplasm of maturing oocysts 
(see Additional file 5). In WT-infected mosquitoes, 30% 
of the oocysts were characterized as degenerate at day 
10, whereas in Pf-PvCSP(vk210) and Pf-PvCSP(vk247) 
infected mosquitoes 52 and 87% degenerate oocysts were 
countedy (Fig.  2b). No spontaneous release of sporozo-
ites from mature pf-pvcsp oocysts was detected and no 
sporozoites could be found free in the haemocoel or in 
salivary glands, even up to day 21 after feeding. Only 
through the application of force to oocysts in dissected 
midguts could mechanically liberated oocyst-derived pf-
pvcsp sporozoites be recovered (Fig. 2a).
Chimeric sporozoites of both pf‑pvcsp(vk210) 
and pf‑pvcsp(vk247) express PvCSP
To analyse expression of PvCSP in pf-pvcsp sporozoites, 
oocyst-derived sporozoites were collected by differen-
tial centrifugation of extracted, mechanically crushed, 
infected midguts. These sporozoites were stained 
a
b
Fig. 2 Oocyst and sporozoite formation of two chimeric P. falciparum parasite lines (pf‑pvcsp) and a PfCSP knockout line (PfΔcsp). a Light 
microscope pictures of oocysts at day 10 after feeding gametocytes to Anopheles stephensi mosquitoes. Upper panel pf‑pvcsp and wild type P. 
falciparum (WT) oocyst in which sporozoite formation occurs (see Additional file 5 for pictures of pf‑pvcsp oocyst that degenerate before sporozoite 
formation). No sporozoite formation was observed in PfΔcsp oocysts. Scale bar, 20 µm. Lower panel: free pf‑pvcsp sporozoites that are released from 
oocysts by application of force to oocysts in dissected midguts. Scale bar, 20 µm. b Percentage of degenerated oocyst in An. stephensi mosquitoes 
(n = 5) at day 10 after feeding (**P = 0.0035, ***P = <0.0001; unpaired T‑test)
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with antibodies specific for PvCSP-VK210, PvCSP-
VK247 and PfCSP. Sporozoites of pf-pvcsp(vk247) and 
pf-pvcsp(vk210) only reacted with their cognate anti-
PvCSP-VK247 or anti-PvCSP-VK210 antibodies and 
WT sporozoites only with anti-PfCSP antibodies (Fig. 3; 
Additional file  6). These results indicate that the corre-
sponding PvCSP is expressed in developing oocysts and 
oocyst-derived sporozoites of the pf-pvcsp lines and that 
the failure of formation of fully competent sporozoites is 
not due to the absence of PvCSP expression.
A P. falciparum NF54 mutant that lacks expression of PfCSP 
forms oocysts but sporozoite formation is absent
To investigate whether the formation of sporozoites in 
chimeric pf-pvcsp oocysts was due to partial complemen-
tation of PfCSP by PvCSP, a P. falciparum mutant lacking 
CSP expression was generated. This mutant (PfΔcsp) was 
generated by disrupting the pfcsp gene by CRISPR/Cas9 
gene editing using a construct (pL0083) that contained an 
mCherry reporter cassette (under control of the constitu-
tive gapdh promoter; see Additional file  7A) flanked by 
pfcsp targeting sequences. This construct is designed to 
replace the pfcsp gene with the mCherry-expression cas-
sette and contains a hdhfr-yfcu drug-selectable marker 
cassette. Transfection of P. falciparum NF54 parasites was 
performed by spontaneous plasmid uptake from plasmid-
loaded red blood cells cultured under static conditions. 
Uninfected RBC were mixed with 50  µg of two sgRNA/
Cas9 constructs (pLf0071 and pLf0072) and 50 µg of the 
donor-DNA construct (pLf0083). After electroporation, 
these uninfected cells were mixed with iRBC containing 
P. falciparum NF54 parasites and selection of transformed 
parasites was performed with the drug WR99210 during 
a period of 6  days. Subsequently the drug was removed 
and parasites were harvested at 0.6–0.8% parasitaemia for 
mCherry fluorescence microscopy analysis to determine 
the ratio of WT and mutant parasites expressing mCherry. 
Parasites were collected from cultures that contained > 80% 
mCherry-positive parasites (at a 4–10% parasitaemia). 
Genotyping of selected and cloned mCherry-positive 
parasites by diagnostic PCR and Southern blot analysis 
showed integration of the mCherry-expression cassette 
into the pfcsp gene (see Additional file 7B, C).
The growth of asexual blood stages in cultures and 
gametocyte production of the PfΔcsp line was compara-
ble to that of WT P. falciparum NF54 parasites (see Addi-
tional file 4; Table 1). Gametocyte cultures of the PfΔcsp 
lines produced WT-like numbers of mature, stage V, 
gametocytes of both sexes. Mature male gametocytes of 
both lines underwent exflagellation upon activation and 
were able to form male gametes (Table 1). Anopheles ste-
phensi mosquitoes were fed with WT gametocytes and 
PfΔcsp gametocytes using standard membrane feeding. 
The number of oocysts was determined at day 10 post 
feeding and the presence of sporozoites in salivary glands 
analysed at day 14 and 21 after feeding. PfΔcsp parasites 
were able to produce oocysts in the mosquitoes but no 
sporozoites were detected in salivary glands after feed-
ing (Table  1). Moreover, sporozoite formation was not 
detected in oocysts (3 exp.; 30 mosquitoes per experi-
ment). All oocysts degenerated before full maturation as 
Fig. 3 PvCSP(VK210) and PvCSP(VK247) expression in oocyst‑derived 
sporozoites of two chimeric P. falciparum parasite lines (pf‑pvcsp). 
Immunofluorescence analyses of wild type P. falciparum (WT) 
sporozoites and oocyst‑derived pf‑pvcsp sporozoites. Fixed 
sporozoites were labelled with mouse anti‑PvCSP‑VK210 mAb, 
anti‑PvCSP‑VK247mAb and mouse anti‑PfCSP antibodies. As a control 
an antibody against PfHSP70 was used. Secondary conjugated 
antibodies used: anti‑IgG Alexa  Fluor® 488 (green) or anti‑IgG 
Alexa Fluor ® 594 (red). Nuclei stained with the DNA‑specific dye 
Hoechst‑33342. All pictures were recorded with standardized 
exposure/gain times; Alexa  Fluor® 488 (green) 0.7 s; anti‑IgG Alexa 
Fluor ® 594 (red) 0.6 s; Hoechst (blue) 0.136 s; bright field 0.62 s (1× 
gain). Scale bar, 7 µm
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shown both by the absence of sporozoite formation and 
the presence of large vacuoles in the cytoplasm of the 
oocysts (see Fig.  2; Additional file  5). This oocyst phe-
notype is comparable to the phenotype observed in P. 
berghei and Plasmodium knowlesi mutants lacking CSP 
expression [42, 43]. The absence of sporozoite forma-
tion in PfΔcsp oocysts is in support of partial comple-
mentation of PfCSP by PvCSP in the pf-pvcsp lines where 
sporozoites are formed in a fraction of the oocysts.
Heterologous CSP replacement and expression in different 
Plasmodium species
Several rodent malaria parasite mutants have been gen-
erated in which their endogenous csp gene has been 
replaced by a csp gene from another Plasmodium species. 
In most of these mutants the heterologous CSP pro-
tein can complement the function of endogenous CSP 
(Table  2). In both Plasmodium yoelii and P. berghei, P. 
falciparum CSP can replace and functionally comple-
ment rodent parasite CSP. In addition, multiple chimeric 
P. berghei lines have been generated that express P. vivax 
CSP alleles (Table  2) and these lines produce salivary 
gland sporozoites that are capable of infecting mice. In P. 
berghei only replacement of PbCSP with CSP of the avian 
malaria parasite Plasmodium gallinaceum did not lead to 
full complementation and pb-pgcsp parasites produced 
strongly reduced numbers of salivary gland sporozoites, 
which are not infective to mice [44]. Recently, the genera-
tion of two chimeric pb-pvcsp lines, expressing the pvcsp 
(vk210/vk247) genes was reported [27]. The pvcsp-210 
Table 2 Parasite lines of different Plasmodium species expressing heterologous or mutated CSP and mutants lacking CSP 
expression
a Expression of heterologous CSP or mutated CSP
b Oocyst numbers and salivary gland sporozoite numbers in infected An. stehensi mosquitoes compared to wild type (WT) infected mosquitoes. WT numbers in the 
same range as WT‑infected mosquitoes
c Mutant ID in the RMgmDB database: https ://www.pberg hei.eu
Plasmodium species CSPa Oocyst no.b Salivary gland 
sporozoite 
no.b
Reference; 
RMgmDB 
 IDc
Remarks (mutation, sporozoite phenotype)
Chimeric CSP parasite lines
 P. berghei Py CSP WT WT [44]; 75
 P. berghei Pf CSP WT Reduced (90%) [52]; 69
 P. berghei Pf CSP WT Reduced (90%) 342
 P. berghei Pf CSP WT WT [53]; 4110
 P. berghei Pf CSP WT WT [54]; 4135
 P. yoelii Pf CSP WT WT [55]; 1442
 P. berghei Pv CSP‑210 WT WT [27]; 4136
 P. berghei Pv CSP‑247 WT WT [28]; 1443
 P. berghei Pv CSP‑247 WT Reduced (30%) [27]; 4137
 P. berghei Pg CSP WT Absent [44]; 74 WT oocyst sporozoite formation
 P. falciparum Pv CSP‑210 WT Absent This study Sporozoite formation in fraction of oocysts
 P. falciparum Pv CSP‑247 WT Absent This study Sporozoite formation in fraction of oocysts
Knock‑out CSP parasite lines
 P. berghei – WT Absent [42]; 9 No sporozoite formation
 P. knowlesi – WT Absent [43] No sporozoite formation
 P. falciparum – WT Absent This study No sporozoite formation
Mutated CSP parasite lines (with a sporozoite production phenotype)
 P. berghei Mut. Pb CSP WT Absent [45]; 72 PbCSP with truncated 3′UTR; reduced sporozoite formation in 
oocysts
 P. berghei Mut. Pb CSP WT Absent [50]; 73 Mutations of the C‑terminal GPI‑anchor. No sporozoite formation 
in oocysts
P. berghei Mut. Pb CSP WT Absent [46]; 1148 PbCSP lacking repeat region; reduced sporozoite formation in 
oocysts; no midgut/salivary gland sporozoites
 P. berghei Mut. Pb CSP WT Absent [46]; 1149 PbCSP lacking repeat region and NH2 terminus; no sporozoite 
formation in oocysts
 P. berghei Pb/Pg CSP WT Absent [56]; 770 pbcsp replaced by pgcsp with repeat region of pbcsp
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and pvcsp247 genes used to generate the chimeric pf-
pvcsp lines described in this study were amplified from 
the constructs used to generate the rodent pb-pvcsp lines. 
The pb-pvcsp lines produced salivary gland sporozoites 
in An. stephensi mosquitoes that were fully infectious to 
mice and these lines have been used to analyse protective 
immunity induced in mice by vaccines that target PvCSP 
[27]. Oocyst formation and sporozoite production of pb-
pvcsp(vk210) was comparable to that of WT parasites but 
sporozoite production of pb-pvcsp(vk247) was reduced 
(Table  2). Oocyst formation and sporozoite production 
of these lines was analysed in more detail and confirmed 
the WT-like formation of oocysts and sporozoites in pb-
pvcsp(vk210) (see Additional file 8). The number of sali-
vary gland sporozoites of pb-pvcsp(vk247) was however 
significantly reduced (P < 0.0001***) compared to WT 
or pb-pvcsp(vk210) parasites (see Additional file  8). By 
analysis of oocysts of both lines at day 14 post feeding, 
we observed increased numbers of degenerated oocysts 
in the pb-pvcsp(vk247), a phenotype that was similar to 
oocysts of the pf-pvcsp lines, i.e. absence of sporozoite 
formation and vacuolated oocyst morphology (see Addi-
tional file 8). These observations indicate that the differ-
ences in numbers of salivary gland sporozoites between 
the P. berghei lines results from a better ability of P. 
vivax CSP(VK210) to complement PbCSP function than 
PvCSP(VK247).
Discussion
Chimeric P. falciparum parasites where the csp gene has 
been replaced with coding sequences of P. vivax csp, 
either Pvcsp(vk210) or Pvcsp(vk247), do not form sali-
vary gland sporozoites. These observations indicate that 
PvCSP cannot functionally complement PfCSP. Although 
PvCSP-expressing sporozoites are formed within oocysts 
of both chimeric lines, most oocysts degenerate before 
sporozoite formation and no sporozoites are released 
from oocysts resulting in the lack of sporozoites in the 
haemocoel or in salivary glands. The inability of P. vivax 
CSP to functionally complement P. falciparum CSP is 
unexpected as studies in the rodent parasite P. berghei 
have shown that the P. berghei CSP can be functionally 
replaced by CSP from different Plasmodium species, 
including the human Plasmodium species, P. vivax and 
P. falciparum (Table  2). Chimeric pb-pvcsp sporozo-
ites expressing the same two PvCSP alleles VK210 and 
VK247, which were used in this study, are able to invade 
An. stephensi salivary glands and are infectious to mice.
CSP is a multifunctional protein that has an essential 
role in the formation of sporozoites inside oocysts as 
well as in sporozoite release, motility and host-cell inva-
sion [9–12]. Mutants of P. berghei and the primate para-
site P. knowlesi lacking CSP expression do form oocysts 
but sporozoite formation inside oocysts is absent [42, 
43]. Maturing oocysts of these csp-deletion mutants are 
highly vacuolated and have no signs of sporozoite forma-
tion that could be detected by light microscopy. In addi-
tion, highly vacuolated oocysts and absence of sporozoite 
formation were observed in mosquitoes fed with the P. 
falciparum mutant lacking CSP, PfΔcsp generated in this 
study. These observations confirm the essential role of 
CSP early in the formation of Plasmodium sporozoites 
and in oocyst maturation.
In contrast to the PfΔcsp parasites, where no sporo-
zoite formation was detected in maturing oocysts, we 
observed Pf-Pvcsp oocysts with sporozoite formation 
and we were able to obtain oocyst-derived sporozo-
ites of both chimeric lines. These sporozoites expressed 
PvCSP as shown by immunofluorescence analysis with 
antibodies specific for either PvCSP VK210 or VK247. 
These observations indicate that the PvCSP proteins can 
be used to initiate sporozoite formation in P. falciparum 
oocysts but are unable to fully complement the function 
of PfCSP in oocyst maturation and sporozoite develop-
ment. Despite the formation of typical elongated sporo-
zoites in some oocysts of Pf-Pvcsp fed mosquitoes, most 
oocysts exhibit a vacuolated morphology and degenerate 
before sporozoite formation. Oocyst degeneration was 
clearly visible from day 10 onwards and between day 10 
and 21 no increase in oocysts with sporozoite formation 
was observed, indicating that the absence of sporozoite 
formation at day 10 is not the result of a delayed matura-
tion of the oocysts. In addition, no evidence was found 
for spontaneous release of sporozoites of the oocysts that 
contained sporozoites and we did not observe haemocoel 
or salivary gland sporozoites in Pf-Pvcsp infected mos-
quitoes up to day 21 post feeding. Free sporozoites were 
only observed when oocysts were ruptured by applying 
mechanical forces on these oocysts.
It seems unlikely that the failure of PvCSP to function-
ally complement PfCSP is due to incorrect expression of 
the PvCSP proteins in the pf-pvcsp lines. The same pvcsp 
genes as used for successful complementation of CSP in 
P. berghei [27] were used to replace P. falciparum csp and 
the pvcsp genes were amplified from the same plasmids 
that were used for generation of the pb-pvcsp lines. In 
addition, the pvcsp gene coding sequence in the genome 
of the pf-pvcsp lines was placed under control of the 
endogenous pfcsp promoter and transcriptional termina-
tor sequences to ensure correct timing and level of CSP 
expression. It has been shown that the 3′ untranslated 
region (3′-UTR) of P. berghei csp plays an important role 
in accurate CSP expression as truncation of pbcsp 3′-UTR 
results in reduced CSP expression, reduced oocyst sporo-
zoite formation and degeneration of oocysts [45].
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The inability of PvCSP to replace the PfCSP function in 
the chimeric pf-pvcsp lines is therefore most likely due to 
sequence differences between these csp genes that lead 
to structural differences of the CSP proteins, which may 
affect interactions with other parasite proteins that are 
essential for proper sporozoite formation. These can be 
protein interactions that influence correct transport of 
CSP from within the oocyst-cytoplasm to the membrane 
of developing sporozoites or interactions that affect its 
localization or maintenance on sporozoites [9–12, 46]. 
Mutational analyses of P. berghei CSP have shown that 
different regions/sequence motifs of CSP are involved in 
correct formation of sporozoites in oocysts (Table 2). The 
overall structure of CSP of different Plasmodium species 
is conserved. CSP is a GPI anchored protein that has a 
central amino acid repeat region, the sequence and num-
ber of repeats varies across Plasmodium species. These 
repeats are flanked by two conserved domains; region I 
at the N terminus of the repeats, and the thrombospon-
din repeat (TSR) domain C-terminal to the repeats [9]. 
The repeat regions of PfCSPs consist of predominantly 
NANP repeats, which differs in length between indi-
vidual P. falciparum strains [47, 48]. The repeat region of 
CSP of two major strains of P. vivax,VK210 and VK247 
are different from PfCSPs to these consists of 10–11 cop-
ies of GDRA(A/D)GQPA or ANGA (G/D)(N/D)QPG 
in CSP-VK210 and CSP-VK247, respectively [49]. The 
GPI-anchor and the repeat region have been shown to 
play an essential role in correct sporozoite formation in 
P. berghei oocysts (Table  2). Mutant parasites express-
ing CSP without GPI-anchor, or with a mutated GPI-
anchor, fail to produce sporozoites and the phenotype is 
similar to mutants that lack CSP expression, i.e. complete 
absence of sporozoite formation [50]. The repeat region 
of CSP appears to play a critical role in the formation 
of P. berghei sporozoites. P. berghei parasites expressing 
mutated CSP lacking only the repeat region are affected 
in the later stages of sporozoite formation [46], a pheno-
type that more closely resembles the phenotype of the 
pf-pvcsp lines. It has been proposed that the CSP repeats 
play a structural role and their absence may result in mis-
folding of CSP and this could affect the interaction of 
CSP with other sporozoite proteins, which are required 
for final oocyst and sporozoite maturation [46]. However, 
P. berghei parasites that lack the N-terminal portion of 
CSP, but retain the signal sequence, the repeat region and 
the C′-terminal region of the protein, can still produce 
salivary gland sporozoites [51].
The phenotype of chimeric P. falciparum expressing 
PvCSP might therefore be explained by a disturbed inter-
action of PvCSP with other P. falciparum proteins, inter-
actions that are mediated by the repeat sequences and 
which are necessary for complete maturation and release 
of oocyst sporozoites. In contrast, it would appear that 
both PvCSP and PfCSP are able to interact with these CSP 
interacting proteins in P. berghei. Plasmodium berghei 
parasites where PbCSP has been replaced with either 
PvCSP(VK210) or PvCSP(VK247) produced infectious 
salivary gland sporozoites, although parasites expressing 
PvCSP(VK247) produced significantly less salivary gland 
sporozoites than either WT or PvCSP(VK210)-express-
ing parasites. Mosquitoes infected with pb-pvcsp(vk247) 
contained degenerate oocysts with a vacuolated mor-
phology that resembled pf-pvcsp parasites. These obser-
vations indicate that PvCSP(VK247) is less effective in 
complementing P. berghei CSP function in sporozoite 
maturation and release from oocysts. However, the pb-
pvcsp(vk247) sporozoites that had invaded the salivary 
glands were not affected in their ability to infect mice.
Further studies using parasites expressing chimeric 
CSP molecules, comprised of different domains of PfCSP 
and PvCSP, are required to reveal which CSP domains are 
essential for sporozoite maturation and release and can 
explain the failure of PfCSP complementation by PvCSP. 
The inability of pf-pvcsp lines to produce salivary gland 
sporozoites means that these lines cannot be used for 
CHMI studies.
Conclusions
Chimeric P. falciparum parasites expressing P. vivax cir-
cumsporozoite protein fail to produce salivary gland 
sporozoites. While PvCSP-expressing sporozoites are 
formed within oocysts, most oocysts degenerate before 
sporozoite formation, no sporozoites are released from 
oocysts to results in the absence of sporozoites in either 
the mosquito haemocoel or salivary glands. Combined, 
these observations show that while PvCSP can partially 
complement the function of PfCSP, species-specific fea-
tures of CSP govern full sporozoite maturation and devel-
opment in the two human malaria parasites.
The inability of P. vivax CSP to functionally comple-
ment P. falciparum CSP is unexpected as studies in the 
rodent parasite P. berghei have shown that the P. berghei 
CSP can be functionally replaced by CSP from different 
Plasmodium species, including the human Plasmodium 
species, P. vivax and P. falciparum. It seems unlikely that 
the failure of PvCSP to functionally complement PfCSP is 
due to incorrect expression of the PvCSP proteins, as the 
same pvcsp genes were used that were able to successfully 
complement the function of CSP in P. berghei. Further 
studies on the role of different CSP elements from differ-
ent Plasmodium species and their potential interactions 
with other Plasmodium proteins may not only reveal 
the species-specific mechanisms that govern sporozoite 
formation and function but may also provide essential 
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information that can be used to create human infectious 
chimeric pf-pvcsp sporozoites.
Additional files
Additional file 1. Vector maps of the P. vivax csp genes introduced into 
P. falciparum. A. Vector maps of the different plasmids used to generate 
two chimeric P. falciparum parasite lines (pf-pvcsp) expressing P. vivax 
CSP(VK210) of CSP(VK247) and a P. falciparum line lacking expression 
of CSP (PfΔcsp). See “Methods” section for description and details of the 
generation of these plasmids.
Additional file 2. List of primers used in this study.
Additional file 3. Sequence analysis of the P. vivax csp genes introduced 
into P. falciparum. Long‑range PCR fragments (see Fig. 1) were cloned into 
pET TOPO TA (Invitrogen) and sequenced. See Additional file 2 for primer 
sequences used for sequencing the complete fragment. A. LR‑PCR frag‑
ment of parasites of pf‑pvcsp(vk210). B. LR‑PCR fragment of parasites of 
pf‑pvcsp(vk247).
Additional file 4. Growth of asexual blood stages and mCherry expres‑
sion in blood stages. Growth of asexual blood stages of two chimeric P. fal-
ciparum parasite lines (pf‑pvcsp(vk210) and pf-pvcsp(vk247), a P. falciparum 
line lacking expression of CSP (PfΔcsp) and P. falciparum wild type (WT) 
parasites. Parasites of the different cloned lines were cultured in semi‑
automated culture system for a period of 7 days. Cultures were initiated 
with a parasitaemia of 0.5%. Arrows indicate the dilution of the cultures 
with fresh red blood cells to have a final parasitaemia of 1%. B. mCherry‑
expressing blood stages of PfΔcsp parasites where the csp gene has been 
disrupted by insertion of an mCherry expression cassette (see Additional 
file 5 for details of the generation of PfΔcsp). Scale bar, 7 µm.
Additional file 5. Degenerated oocysts of two chimeric P. falciparum 
parasite lines (pf-pvcsp) and a PfCSP knockout line (PfΔcsp). Light micro‑
scope pictures of degenerated oocysts at day 10 after feeding gameto‑
cytes to Anopheles stephensi mosquitoes. These oocysts are classified as 
degenerate based on the absence of sporozoite formation and vacuolated 
cytoplasm. See Fig. 2 for pf-pvcsp and wild type P. falciparum (WT) oocyst 
in which sporozoite formation occurred. No sporozoite formation was 
observed in PfΔcsp oocysts. Scale bar, 20 µm.
Additional file 6. PvCSP(VK210) and PvCSP(VK247) expression in oocyst‑
derived sporozoites of two chimeric P. falciparum parasite lines (pf-pvcsp). 
Immunofluorescence analyses of wild type P. falciparum (WT) sporozoites 
and oocyst‑derived pf-pvcsp sporozoites. Fixed sporozoites were labelled 
with mouse anti‑PvCSP‑VK210 mAb, anti‑PvCSP‑VK247mAb and mouse 
anti‑PfCSP antibodies. Secondary conjugated antibodies used: anti‑IgG 
Alexa Fluor® 488 (green. Nuclei stained with the DNA‑specific dye Hoe‑
chst‑33342. All pictures were recorded with standardized exposure/gain 
times; Alexa Fluor® 488 (green) 0.7 s; Hoechst (blue) 0.136 s; bright field 
0.62 s (1× gain). Scale bar, 7 µm.
Additional file 7. Generation and genotyping a P. falciparum mutant 
line lacking expression of CSP (PfΔcsp). A. The PfΔcsp line was generated 
using CRISPR/Cas9 methodology. The pfcsp gene was replaced by inser‑
tion of a mCherry expression cassette (mCherry under control of the of 
the constitutive gapdh promoter) using donor‑DNA plasmids pLf0086. A 
schematic representation of the pfcsp locus before and after insertion of 
the construct showing the location of the restriction sites (A: AvaII), sizes 
(in bp) of restriction fragments (red for Southern blot analysis), location 
of primers (p), PCR amplicons and sizes of the fragments (in black) used 
to analyse correct disruption of the pfcsp and insertion of the mCherry 
cassette (B, C). HR1, HR2: pfcsp homology (targeting) regions. The figure 
is not shown to scale. Primer sequences can be found in Additional file 8. 
B. Diagnostic PCR confirming correct integration of the mCherry cassette 
into the PfCSP locus. 5′ integration PCR (lane 2; primers p15/p19); pfcsp 
open reading frame (lane 3; primers p17/p18); P. falciparum sequestrin as 
a control gene (lane 1; primers p22/p23); mCherry gene (lane 4; primers 
P20/P21) of cloned parasites of PfΔcsp (cl3) and WT. C. Southern blot 
analysis of AvaII/XhoI restricted DNA of WT and PfΔcsp parasites confirms 
the specific integration of the mCherry cassette into the pfcsp gene locus. 
DNA was hybridized with a probe targeting the homology region 2 (upper 
panels; HR2; primers p3/p4; see (A) of pfcsp. The hybridization pattern 
observed with the HR2 probe identified the expected different‑sized DNA 
fragments in WT and pf-pvcsp parasites (2057 bp and 4105 bp). In addition 
to show absence of donor‑DNA plasmid and presence of single cross‑over 
events DNA was hybridized with a probe for the ampicillin gene (lower 
panels; intermediate donor‑DNA plasmid pLf0040 digested with AatII and 
PvuI).
Additional file 8. Chimeric rodent parasite lines pb-pvcsp(vk210) and 
pb-pvcsp(vk247) are able to produce salivary gland sporozoites that are 
infectious to mice. A. Upper panel, left: Light microscope pictures of 
wild type P. berghei (WT) and pb-pvcsp oocyst at days 7, 10 and 14 after 
feeding of An. stephensi mosquitoes. Black arrows indicate oocyst with 
sporozoite formation and white arrows indicate degenerated, vacuolated 
oocyst without sporozoite formation (scale bar, 10 µm). Upper panel, right, 
Percentage of degenerated oocyst in An. stephensi mosquitoes (n = 5) at 
day 14 after feeding (***P = < 0.0001; unpaired T‑test). Lower panel: Oocyst 
and sporozoite production of wild type P. berghei (WT) and pb-pvcsp para‑
sites. B. In vivo imaging of parasite liver loads at 44 h after injection of mice 
with salivary gland sporozoites of wild type P. berghei (WT) and pb-pvcsp 
parasites. Left panel: luminescence signals in the different groups of mice. 
Right panel: quantification of the bioluminescence signals in the different 
groups of mice measured as Relative Luminescence Units (RLU).
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